Core Viewpoint - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, with a corporate overview presentation scheduled at the 2025 BIO CEO & Investor Conference [1][2]. Company Overview - Lisata Therapeutics is dedicated to the discovery, development, and commercialization of therapies targeting advanced solid tumors and major diseases [3]. - The company's investigational drug, certepetide, is designed to activate a novel uptake pathway for more effective targeting and penetration of solid tumors by anti-cancer drugs [3]. - Lisata has established significant commercial and R&D partnerships based on its CendR Platform® technology [3]. - The company anticipates announcing numerous milestones over the next 1.5 years and believes its projected capital will fund operations into early 2026, including data milestones from ongoing and planned clinical trials [3].
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference